Paeonol as a Multi‐Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection
Immunity, Inflammation and Disease · 2026
DOI: 10.1002/iid3.70494 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Md Sakib Al Hasan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gopalganj Science and Technology University, Gopalganj, Bangladesh. Hauptthemen laut MEDLINE: Neuroprotective Agents, Acetophenones, Nervous System Diseases, Neurodegenerative Diseases. Die Arbeit nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neurological disorders are a major global health challenge in the current era, and they need new therapeutic treatments.
Aims
This review evaluates the neurobiological activity of Paeonol (PNL) focusing on its antioxidant, anti‐inflammatory, and cognitive enhancing effects in various neurodegenerative disorders.
Methods
A literature search (up to March 2025) was conducted via PubMed, ScienceDirect, Scopus, and other databases using MeSH terms related to PNL's pharmacology and neuroprotection. Inclusion criteria encompassed preclinical studies (in vitro and in vivo) and clinical trials, while exclusion criteria eliminated non‐English papers and non‐neurodegenerative research.
Results
PNL, a bioactive phenolic compound from Paeonia suffruticosa , has shown antioxidative, anti‐inflammatory, and neuroprotective effects. PNL reduces oxidative stress by boosting the activity of superoxide dismutase (SOD) and glutathione (GSH) while decreasing reactive oxygen species (ROS) and lipid peroxidation. It also reduces neuroinflammation by inhibiting key pathways such as nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), toll‐like receptor 4 (TLR4), and mitogen‐activated protein kinase (MAPK), and it affects apoptosis‐related proteins like B‐cell lymphoma 2 (Bcl‐2) and Bcl‐2‐associated X protein (Bax). In Alzheimer's disease (AD) models, PNL reduces amyloid‐β plaques and some pro‐inflammatory cytokines like interleukin‐1 beta (IL‐1β) and tumor necrosis factor‐alpha (TNF‐α), improving cognitive function. For ischemic stroke, it reduces infarction volume and microglial activation by targeting TLR2/4 and NF‐κB. PNL has anticonvulsant effects in epilepsy and protects dopaminergic neurons in Parkinson's disease (PD). It also demonstrates anxiolytic and antidepressant properties by modulating Brain‐Derived Neurotrophic Factor (BDNF), Nerve Growth Factor (NGF), and oxidative stress markers. PNL is quickly absorbed with moderate bioavailability and low blood–brain barrier permeability. It effectively treats unstable angina but is less effective for osteoarthritis pain. Though safe at therapeutic doses, high concentrations can be cytotoxic.
Conclusion
Further clinical research is needed to confirm its neurotherapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Gopalganj Science and Technology University, Gopalganj, Bangladesh.
- Department of Pharmacy, Khwaja Yunus Ali University, Enayetpur, Sirajganj, Bangladesh.
- Department of Pharmacy, Islamic University, Kushtia, Bangladesh.
- Central Labs, King Khalid University, Abha, Saudi Arabia.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
ORCID-Profile: Md Sakib Al Hasan, Naznin Shahria, Yasin Emon, Mohammad Y Alshahrani, Emon Mia, Faisal H Altemani, Umme Habiba Sumaya, Md Torequl Islam
Zitieren
APA
Al Hasan, M. S., Shahria, N., Emon, Y., Alshahrani, M. Y., Mia, E., Altemani, F. H., Suma, R. B., Sumaya, U. H., Uddin, M. B., & Islam, M. T. (2026). Paeonol as a Multi‐Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70494
Vancouver
Al Hasan MS, Shahria N, Emon Y, Alshahrani MY, Mia E, Altemani FH, et al. Paeonol as a Multi‐Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70494
BibTeX
@article{AlHasan2026,
author = {Al Hasan, Md Sakib and Shahria, Naznin and Emon, Yasin and Alshahrani, Mohammad Y and Mia, Emon and Altemani, Faisal H and Suma, Rituparna Biswas and Sumaya, Umme Habiba and Uddin, Mohammed Burhan and Islam, Md Torequl},
title = {Paeonol as a Multi‐Target Therapy for Neurological Disorders: Mechanistic Insights Into Neuroprotection},
journal = {Immunity, Inflammation and Disease},
year = {2026},
doi = {10.1002/iid3.70494}
}
EUVIMED